Liu X Y, Qu X J, Tang W
Drug Discov Ther. 2007 Aug;1(1):2.
Viral hepatitis is currently a major global cause of morbidity and mortality. In some Asian countries like China and Japan, Hepatitis B and C in particular are the most common extremely infectious diseases and are likely to develop into liver cirrhosis. Furthermore, statistics indicate that patients with liver cirrhosis resulting from hepatitis B and C have an increased risk of developing hepatocellular carcinoma (HCC). Scientists have worked tirelessly to find curative therapeutic strategies to control chronic hepatitis and liver cirrhosis, accompanied by improvements in public health and living conditions. China's Shandong University and the University of Tokyo in Japan previously established a longterm cooperative relationship. Cooperative programs include co-training of postgraduates, exchanges of visiting scholars, academic symposia, and a bilateral international joint research program. Some substantive progress has been made as a result of bilateral endeavors. For instance, the Shandong University China-Japan Cooperation Center for Drug Discovery & Screening (SDU-DDSC) has enhanced to serve as an important platform for further close cooperation. At the same time, the International Advancement Center for Medicine & Health Research (IACMHR) - "Drug Discoveries and Therapeutics" and International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) - "BioScience Trends" were established (Visit http://www.ddtjournal.com and http://www.biosciencetrends.com ). The first China-Japan conference on new drug discoveries and therapeutics (CJMWDDT 2007) was recently held in Jinan, China May 27-29, 2007, which provided opportunities for further communication and cooperation and increased knowledge of new drug research and clinical cures for hepatitis. Financially supported by the National Natural Science Foundation of China (NSFC) and the Japan Society for the Promotion of Science (JSPS), the conference covered a wide range of topics in different areas of chemical biology, phytochemistry, medicinal chemistry, and pharmacology and it resulted in informed and genial discussions of hepatitis cures that yielded fruitful results. The active involvement and participation by attendees gave the conference a congenial atmosphere. In the end, an agreement was reached to work together on new drug discovery and effective hepatitis therapeutic strategies, and some agreements have resulted in the creation of handover protocols. The CJMWDDT 2007 was a highly successful scientific event that strengthened and promoted extensive cooperation between China and Japan for the development of new pharmaceutical products and hepatitis cures.
病毒性肝炎是当前全球发病和死亡的主要原因。在一些亚洲国家，如中国和日本，乙型和丙型肝炎尤其常见，是极具传染性的疾病，且很可能发展为肝硬化。此外，统计数据表明，由乙型和丙型肝炎导致肝硬化的患者患肝细胞癌（HCC）的风险增加。伴随着公共卫生和生活条件的改善，科学家们一直在不懈努力寻找控制慢性肝炎和肝硬化的有效治疗策略。中国山东大学与日本东京大学此前建立了长期合作关系。合作项目包括联合培养研究生、互派访问学者、举办学术研讨会以及开展双边国际联合研究项目。双方的努力取得了一些实质性进展。例如，山东大学中日药物发现与筛选合作中心（SDU - DDSC）得到了加强，成为进一步密切合作的重要平台。同时，成立了国际医学与健康研究推进中心（IACMHR）——《药物发现与治疗》以及生物与社会科学进步国际研究与合作协会（IRCA - BSSA）——《生物科学趋势》（访问http://www.ddtjournal.com和http://www.biosciencetrends.com）。首届中日新药发现与治疗会议（CJMWDDT 2007）于2007年5月27日至29日在中国济南举行，此次会议为进一步的交流与合作提供了机会，增进了对肝炎新药研究和临床治疗的了解。在中国国家自然科学基金（NSFC）和日本学术振兴会（JSPS）的资助下，会议涵盖了化学生物学、植物化学、药物化学和药理学等不同领域的广泛主题，对肝炎治疗进行了深入且友好的讨论，取得了丰硕成果。与会者的积极参与为会议营造了融洽的氛围。最后，就新药研发和有效的肝炎治疗策略达成了合作共识，一些共识促成了交接方案的制定。CJMWDDT 2007是一次非常成功的科学活动，加强并促进了中日两国在新药研发和肝炎治疗方面的广泛合作。
